JERUSALEM, June 1 (Xinhua) -- Israeli researchers have developed a "groundbreaking" bio-sensing technology that predicts which cancer patients will positively respond to immunotherapy, Israel's Ben Gurion University (BGU) said on Thursday.
The new method, developed in a new study published in the journal Science Advances on May 26, accurately predicts the response of cancer patients to the leading anti-PD1 therapy that disrupts immune suppression to fight tumors, BGU said in a statement posted on its website.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
